Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.

Cancer science - 1 Mar 2018

Katayama Ryohei

Abstract excerpt

The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, and many kinds of ALK fusion genes have been found in a variety of carcinomas. There is almost no detectable expression of ALK in adults. However, through ALK gene rearrangement, the resultant ALK fusion protein is aberrantly overexpressed and dimerized through the oligomerization domains, such as the coiled-coil domain, in the fusion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Clinical Trials as Topic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Genomic Instability

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 29336091
DOI: 10.1111/cas.13504
PMCID: PMC5834792

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.PMID 29336091Read ↗

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read ↗

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung CancerSemantic proximity Read ↗

Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Semantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung CancerSemantic proximity Read ↗

Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.Semantic proximity Read ↗

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Acquired resistance in oncogene-addicted non-small-cell lung cancer.Semantic proximity Read ↗

[Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].Semantic proximity Read ↗

ALK alterations and inhibition in lung cancer.Semantic proximity Read ↗

The battle against ALK resistance: successes and setbacksSemantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.